These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Intravitreal bevacizumab for uveitic choroidal neovascularization.
    Author: Doctor PP, Bhat P, Sayed R, Foster CS.
    Journal: Ocul Immunol Inflamm; 2009; 17(2):118-26. PubMed ID: 19412874.
    Abstract:
    PURPOSE: To report 5 cases of inflammatory choroidal neovascularization (CNV) that were treated with intravitreal bevacizumab. METHODS: Six eyes of 5 patients with uveitic CNV were treated with 2.5 mg/0.1 mL of intravitreal bevacizumab. Main outcome measures were the changes in BCVA and reduction in the size of the CNV. RESULTS: The mean follow-up time was 15.3 months. The mean intravitreal injections administered were 2.7. All patients showed a reduction in the size of the CNV with improvement in BCVA in 60% of cases at the last follow-up. CONCLUSION: Intravitreal bevacizumab may provide an additional strategy in the management of inflammatory CNV.
    [Abstract] [Full Text] [Related] [New Search]